Table 1 Characteristics of individual studiesa
Study | Location | Design (comparison) | Number (n) | Age (years) | Gender (male) (n (%)) | Pre-treatment (n) | Method of administering rhsTM | Other treatment for AE (n) | Anticoagulant for control group (n) |
|---|---|---|---|---|---|---|---|---|---|
Sakamoto 2018 [32] | Japan | Retrospective (historical control) | 45 vs. 35 | Median (range) 75 (56–86) vs. 75 (59–82) | 40 (88.9) vs. 28 (80.0) | Pir 9 vs. 7 Cs 11 vs. 9 IS 6 vs. 3 | 0.06 mg/kg/d for 6 days | mPSL all IS (CsA) 66 | LMWH (75 IU /kg/d for 14 days) (6) |
Hayakawa 2016 [36] | Japan | Prospective (historical control) | 10 vs. 13 | Mean (SD) 73.2 (9.5) vs. 69.7 (8.5) | 8 (80.0) vs. 11 (84.6) | Pir 2 vs. 0 | 380 U/kg/d for 7 days | mPSL all IS 0 vs. 6 | – |
Tsushima 2014 [37] | Japan | Retrospective (historical control) | 20 vs. 6 | Mean (SE) 76.2 (0.4) vs. 73.7 (1.2) | 14 (70.0) vs. 6 (100.0) | – | 0.06 mg/kg/d for 6 days | mPSL all | – |
Kataoka 2015 [38] | Japan | Retrospective (historical control) | 20 vs. 20 | Median (IQR) 73.5 (69.0–78.0) vs. 71.0 (64.8–78.0) | 17 (85.0) vs. 19 (95.0) | Pir 5 vs. 2 Cs 3 vs. 4 | 0.06 mg/kg/d for median 6 days (range 3–6) | mPSL all IS (CsA) all | LMWH (75 IU/kg/d for median 10 days (range 7–22)) (20) |